N@N

Adnan Butt Initiated (BIIB) at Strong Buy and Held Target at $402 on, Oct 24th, 2017

Adnan Butt of Guggenheim, Initiated "Biogen Inc." (BIIB) at Strong Buy and Held Target at $402 on, Oct 24th, 2017.

Adnan has made no other calls on BIIB in the last 4 months.

There are 11 other peers that have a rating on BIIB. Out of the 11 peers that are also analyzing BIIB, 5 agree with Adnan's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Robyn Karnauskas of "Citigroup" Downgraded from Strong Buy to Hold on, Monday, October 23rd, 2017
• Brian Abrahams of "RBC Capital" Initiated at Hold and Held Target at $319 on, Friday, September 15th, 2017
• Jeffrey Silber of "BMO Capital" Maintained at Hold with Increased Target to $377 on, Wednesday, September 13th, 2017
• Carter Gould of "UBS" Maintained at Hold with Increased Target to $285 on, Wednesday, July 26th, 2017
• Eun Yang of "Jefferies" Initiated at Hold and Held Target at $310 on, Tuesday, July 11th, 2017

These are the ratings of the 6 analyists that currently disagree with Adnan

---

• Christopher Raymond of "Piper Sandler" Initiated at Buy and Held Target at $390 on, Monday, October 23rd, 2017
• Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $365 on, Wednesday, October 18th, 2017
• Thomas Shrader of "Stifel" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
• Salim Syed of "Mizuho" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
• Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Thursday, October 5th, 2017
• Terence Flynn of "Goldman Sachs" Upgraded at Strong Buy on, Wednesday, August 16th, 2017

Contributing Sources

---